Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products

This article was originally published in The Pink Sheet Daily

Executive Summary

Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.

You may also be interested in...



Epizyme Builds A Cancer Company At Mach Speed

Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.

Ligand Takes Out Neurogen For At Least $11 Million

Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.

Ligand Takes Out Neurogen For At Least $11 Million

Continuing its rebound from the Third Point fight, Ligand issues a sliver of stock to take control of Neurogen.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel